Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline

Fineline Cube Jul 16, 2026
Company Deals

Braveheart Bio Files IPO Prospectus with Nasdaq for $1.8B Cardiac Myosin Inhibitor Asset

Fineline Cube Jul 16, 2026
Company Deals

WuXi Biologics Enters CDRMO Partnership with CANbridge Through 2028

Fineline Cube Jul 16, 2026
Company Deals

Innovent Biologics Secures $1.1B Global CD40L Antibody Deal with Spero Therapeutics

Fineline Cube Jul 15, 2026
Company Deals

Hansoh Pharmaceutical Secures $2.3B IL-23 Deal and Strategic Stake in Avere-NextCure Merger

Fineline Cube Jul 15, 2026
Policy / Regulatory

China’s CDE Releases Draft Guideline for Real-World Evidence-Based Pediatric Indication Expansion of Marketed Drugs

Fineline Cube Jul 16, 2026
Company Drug

InnoCare Pharma’s Soficitinib Meets Primary Endpoint in Phase III Atopic Dermatitis Trial as Highly Selective TYK2 Inhibitor

Fineline Cube Jul 16, 2026
Company Drug

Amoytop Biotech Secures NMPA Clinical Trial Approval for ACT201, Novel ASO Therapy for Chronic Hepatitis B

Fineline Cube Jul 16, 2026
Company

Sihuan Pharmaceutical Restructures with Dual Organization Model

Fineline Cube Aug 17, 2022

China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) announced a structural reshuffling, setting up a...

Company Deals

Baheal Pharmaceutical Partners with Takeda to Boost Drug Commercialization in China

Fineline Cube Aug 17, 2022

China-based health services and distribution giant Baheal Pharmaceutical Group has entered into a partnership with...

Company Drug

Belief-Delivery BioMed’s BBM-H901 Granted BTD for Hemophilia B Prevention

Fineline Cube Aug 17, 2022

The Center for Drug Evaluation (CDE) website indicates that Shanghai Belief-Delivery BioMed Co., Ltd’s injectable...

Company Deals

Wyze Biotech Raises RMB59m to Advance DNT Cell Therapies

Fineline Cube Aug 17, 2022

Wyze Biotech Co., Ltd, a Guangdong-based developer of off-the-shelf universal DNT cell therapies, has reportedly...

Company Drug

Sanjin Pharma’s Subsidiary Gets NMPA Nod for BC007 Cancer Study

Fineline Cube Aug 17, 2022

China-based Guilin Sanjin Pharmaceutical Co. Ltd (SHE: 002275) announced that its subsidiary, Dragon Boat Biopharmaceutical...

Company Drug

I-Mab and AbbVie End CD47 Antibody Trial but Continue Collaboration

Fineline Cube Aug 17, 2022

China-based biotech I-Mab (NASDAQ: IMAB) filed with the US Securities and Exchange Commission (SEC) that...

Company Deals

Menovo Pharmaceutical Plans RMB892m Private Placement to Boost API Production

Fineline Cube Aug 17, 2022

China-based Ningbo Menovo Pharmaceutical Co., Ltd (SHA: 603538) has announced plans to raise up to...

Company Deals

BeiGene Partners with Ontada to Accelerate RWE Development in US Oncology Market

Fineline Cube Aug 17, 2022

China-based biotech company BeiGene (HKG: 6160, SHA: 688235, NASDAQ: BGNE) announced that it has signed...

Company Drug

Grand Pharmaceutical’s Carglumic Acid Set for Priority Review by CDE

Fineline Cube Aug 17, 2022

The Center for Drug Evaluation (CDE) website indicates that China-based Grand Pharmaceutical Group Limited’s (HKG:...

Company Drug

Ascletis Pharma’s Gannex Initiates DDI Study for ASC42 in PBC

Fineline Cube Aug 16, 2022

Ascletis Pharma Inc. (HKG: 1672) announced that its wholly – owned US unit, Gannex, has...

Company Medical Device

Venus Medtech’s VenusP-Valve Used Again in US Compassionate Case

Fineline Cube Aug 16, 2022

Venus Medtech (Hangzhou) Inc. (HKG: 2500) announced the second US market compassionate use of its...

Drug

Luye Pharma’s Goserelin Acetate Injectable Accepted for Breast Cancer Review

Fineline Cube Aug 16, 2022

China-based Luye Pharma Group (HKG: 2186) announced that another market filing for its goserelin acetate...

Company Deals

Healthnice Pharma Raises RMB100m to Expand Product Pipeline and R&D Team

Fineline Cube Aug 16, 2022

China-based Nanjing Healthnice Pharmaceutical Technology Co., Ltd has reportedly raised RMB100 million (USD14.8 million) in...

Company Deals

Healthnice Pharma Raises RMB100m to Expand Product Pipeline and R&D Team

Fineline Cube Aug 16, 2022

China-based Nanjing Healthnice Pharmaceutical Technology Co., Ltd has reportedly raised RMB100 million (USD14.8 million) in...

Company Deals

Gilead Transfers Trodelvy Asian Rights to Everest Medicines for USD280m

Fineline Cube Aug 16, 2022

US pharmaceutical major Gilead Sciences Inc. (NASDAQ: GILD) today announced an agreement with Everest Medicines...

Company Drug

CDE Prioritizes Review for Sanofi’s Nexviazyme and WinHealth’s Ravicti

Fineline Cube Aug 16, 2022

The Center for Drug Evaluation (CDE) website indicates that two drugs have been selected for...

Company Drug

Henlius Biotech’s HanBeiTai sBLA Accepted for HCC Treatment Review

Fineline Cube Aug 16, 2022

Shanghai Henlius Biotech Inc. (HKG: 2696) announced that a supplementary Biologic License Application (sBLA) for...

Company Drug

Alphamab Oncology Doses First Patient in KN046-209 Study for NSCLC

Fineline Cube Aug 16, 2022

China-based Alphamab Oncology (HKG: 9966) announced the first patient dosing in the multi-center, open-label Phase...

Company Drug

Roche’s Rozlytrek Wins NMPA Approval for ROS1+ NSCLC Treatment

Fineline Cube Aug 15, 2022

Swiss pharmaceutical giant Roche’s China unit announced that it has received market approval from the...

Company

EQRx Accelerates US Development of Two Chinese-Licensed Cancer Drugs

Fineline Cube Aug 15, 2022

US-based pharma EQRx Inc. (Nasdaq: EQRX) has revealed its latest plans to accelerate the US...

Posts pagination

1 … 666 667 668 … 696

Recent updates

  • InnoCare Pharma’s Soficitinib Meets Primary Endpoint in Phase III Atopic Dermatitis Trial as Highly Selective TYK2 Inhibitor
  • Amoytop Biotech Secures NMPA Clinical Trial Approval for ACT201, Novel ASO Therapy for Chronic Hepatitis B
  • Boehringer Ingelheim Reports 16.2% H1 2026 Sales Growth Driven by JARDIANCE and New Oncology Launches
  • China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline
  • Harbour BioMed and Kelun-Biotech Secure NMPA IND Approval for HBM7575/SKB575, Long-Acting Bispecific Antibody for Asthma
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

InnoCare Pharma’s Soficitinib Meets Primary Endpoint in Phase III Atopic Dermatitis Trial as Highly Selective TYK2 Inhibitor

Company Drug

Amoytop Biotech Secures NMPA Clinical Trial Approval for ACT201, Novel ASO Therapy for Chronic Hepatitis B

Company

Boehringer Ingelheim Reports 16.2% H1 2026 Sales Growth Driven by JARDIANCE and New Oncology Launches

Company Deals

China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.